PDF Cover

Iopromide Market

The market for Iopromide was estimated at $536 million in 2024; it is anticipated to increase to $744 million by 2030, with projections indicating growth to around $977 million by 2035.

Report ID:DS1802217
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Iopromide
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Iopromide Market Outlook

Revenue, 2024

$536M

Forecast, 2034

$924M

CAGR, 2025 - 2034

5.6%

The Iopromide industry revenue is expected to be around $566.3 million in 2025 and expected to showcase growth with 5.6% CAGR between 2025 and 2034. This steady growth trajectory highlights the increasing importance of iopromide in modern diagnostic imaging and clinical decision-making. The rising prevalence of chronic diseases, particularly cardiovascular and neurological disorders, is driving demand for accurate and timely imaging procedures. Healthcare systems are placing greater emphasis on early diagnosis and minimally invasive techniques, which is reinforcing the use of contrast agents in routine clinical workflows. Additionally, expanding access to advanced imaging infrastructure in emerging markets is supporting broader adoption. Continuous improvements in formulation safety, reduced adverse reactions, and enhanced imaging clarity are further strengthening its relevance. Strategic collaborations between pharmaceutical companies and healthcare providers are also contributing to consistent supply and improved distribution networks, ensuring sustained market demand.

Iopromide, also known as Ultravist, is a non-ionic, water-soluble iodinated contrast agent widely used in radiographic imaging procedures. It is primarily utilized in computed tomography scans, angiography, and urography to enhance the visibility of blood vessels, organs, and tissues. Key features include high radiopacity, low osmolality, and favorable safety profile, which help minimize patient discomfort and reduce the risk of adverse reactions. Its versatility makes it suitable for a wide range of diagnostic applications across cardiology, oncology, and neurology. Recent trends driving demand include the growing use of high-resolution imaging technologies, increasing number of diagnostic procedures, and advancements in contrast media delivery systems. Additionally, ongoing research aimed at improving patient safety and imaging efficiency continues to support its adoption in global healthcare settings.

Iopromide market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Iopromide Market Outlook

Market Key Insights

  • The Iopromide market is projected to grow from $536.3 million in 2024 to $925 million in 2034. This represents a CAGR of 5.6%, reflecting rising demand across Computed Tomography, Angiography, and Urography.

  • Bayer Healthcare is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Iopromide market and are expected to observe the growth CAGR of 3.6% to 5.4% between 2024 and 2030.

  • Emerging markets including Brazil, South Korea and Saudi Arabia are expected to observe highest growth with CAGR ranging between 6.4% to 7.7%.

  • Industry players are pushing the adoption of transitions like Transition from Conventional Imaging Support to Integrated Diagnostic Workflow Solutions for future years due to existing low growth of 5.6% ; but are also expected to invest $26 million by 2030.

  • The Iopromide market is set to add $388 million between 2024 and 2034, with manufacturer targeting Angiography & Urography Application projected to gain a larger market share.

  • With

    advancements in medical imaging, and

    Increased Incidence of Chronic Diseases, Iopromide market to expand 72% between 2024 and 2034.

iopromide market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Iopromide - Country Share Analysis

Opportunities in the Iopromide

A major opportunity for iopromide lies in the rapid expansion of advanced diagnostic imaging centers, particularly those equipped with high-resolution CT and angiography systems. As healthcare providers invest in early and accurate disease detection, the demand for reliable iodinated contrast agents is also rising steadily. Iopromide is expected to see strong growth in computed tomography applications due to its favorable safety profile and imaging clarity. This trend is especially prominent in urban healthcare networks where patient volumes are high and precision diagnostics are critical for treatment planning.

Growth Opportunities in North America and Asia-Pacific

With its advanced healthcare system, North America represents a significant market for Iopromide. The increasing prevalence of chronic diseases demanding diagnostic imaging has led to a surge in the use of contrast agents such as Iopromide. In addition, strong investment in medical research and development, along with established hospital networks, create a conducive environment for market growth. However, the intensity of competition in this region is high, with numerous established players such as Bayer and GE Healthcare adding to the competitive pressure. Key market drivers include the growing geriatric population, advancements in diagnostic imaging technologies, and increased use of personalized medicine.
In Asia-Pacific, the market for Iopromide is rapidly growing due to increasing healthcare expenditure and growing awareness about early disease detection. The presence of a large patient pool, amplified by the rapidly growing ageing population, is set to increase the demand for diagnostic tests in which Iopromide is used. However, fierce competition from local and international players, along with regulatory challenges, could pose potential hurdles. Key drivers in the Asia-Pacific region include increasing investments in healthcare infrastructure, rising incidence of chronic diseases, and the implementation of several government initiatives aimed at improving healthcare outcomes.

Market Dynamics and Supply Chain

01

Driver: Growing Demand for Advanced Imaging and Rising Incidence of Chronic Diseases

The global iopromide market is also significantly driven by the rising demand for advanced diagnostic imaging procedures. Computed tomography and angiography are also increasingly used in hospitals and diagnostic centers to detect cancers, cardiovascular diseases, and neurological conditions at early stages. As clinicians adopt sophisticated imaging systems, they require reliable low-osmolar, non-ionic contrast agents like iopromide to ensure high-resolution images with minimal patient discomfort. In parallel, the incidence of chronic diseases such as cancer, stroke, and heart disease continues to grow due to aging populations and lifestyle factors, prompting more frequent use of contrast-enhanced imaging. This dual growth in imaging utilization and chronic disease prevalence expands market opportunities for iopromide, particularly in regions with improving healthcare infrastructure and increased access to diagnostic services. Hospitals and outpatient imaging facilities increasingly integrate iopromide into standard protocols for enhanced diagnostic accuracy.
The evolution of low-osmolar, non-ionic contrast media also represents a pivotal driver for iopromide adoption. Innovations in molecular design have also reduced osmolality and improved tolerability compared to traditional ionic agents, resulting in fewer adverse reactions during diagnostic imaging. These advancements support broader clinical acceptance among radiologists and clinicians, who prioritize both image quality and patient safety. Improved contrast formulations enable higher patient throughput in CT and angiographic procedures, addressing operational needs in busy hospitals. As healthcare providers seek safer, more effective agents, iopromide’s refined profile strengthens its position in competitive imaging markets and supports sustained demand growth.
02

Restraint: Safety Concerns and Adverse Reactions Limiting Clinical Adoption

Despite its widespread use, iopromide’s growth is restrained by safety concerns related to iodine-based contrast agents. Adverse reactions such as allergic responses and potential nephrotoxicity in patients with impaired renal function reduce clinician willingness to use iopromide in vulnerable populations, particularly in geriatric and comorbid cases. These risks prompt healthcare providers to prefer alternative agents or non-contrast imaging modalities, lowering procedure volumes that rely on iopromide. For example, reports of hypersensitivity reactions can deter use in outpatient settings, reducing overall market demand and negatively impacting revenue growth. Such safety limitations influence decision-making at hospitals and diagnostic centers, restricting broader market expansion.
03

Opportunity: Growing adoption in cardiovascular imaging procedures across aging patient populations worldwide and Expanding healthcare infrastructure and diagnostic access in emerging economies regions

The rising prevalence of cardiovascular diseases among aging populations is creating significant demand for iopromide in angiography and interventional imaging procedures. Hospitals and specialty cardiac centers are increasingly relying on high-quality contrast agents to improve visualization of blood vessels and detect blockages accurately. Iopromide is particularly suited for these applications due to its low osmolality and reduced risk of adverse reactions. Growth is expected to be strongest in developed regions with aging demographics, where advanced cardiac imaging procedures are becoming more routine and essential for effective disease management.
Emerging economies present a strong growth opportunity for iopromide as healthcare infrastructure continues to improve and access to diagnostic imaging expands. Governments and private sector investments are increasing the number of hospitals and imaging facilities, particularly in Asia Pacific and Latin America. This expansion is driving demand for cost-effective and efficient contrast media for routine diagnostic procedures. Iopromide adoption is expected to grow in general radiology and CT imaging segments, supported by rising healthcare awareness, increasing patient volumes, and gradual improvements in reimbursement systems across these regions.
04

Challenge: High Costs and Stringent Regulatory Requirements Increasing Market Barriers

The iopromide market faces significant restraints from elevated production and compliance costs combined with rigorous regulatory environments. Manufacturers incur substantial expenses related to safety evaluations, quality certifications, and documentation, which slow product approvals and increase time-to-market. This is particularly challenging for smaller firms unable-to absorb high R&D and regulatory compliance costs, limiting their ability to innovate or compete. Additionally, the high cost of contrast agents and associated imaging procedures burdens healthcare budgets, especially in low- and middle-income regions, reducing access and dampening demand. For instance, constrained healthcare spending in developing markets restricts adoption of advanced imaging contrast media.

Supply Chain Landscape

1

Material Suppliers

Chemical Manufacturers AssociationSynoptica Ltd
2

Intermediate Producers

Sigma-Aldrich CorporationFagron Group BV
3

Product Manufacturers

Bayer HealthcareGE Healthcare
4

End-use

Diagnostic CentersHospitalsPharmaceutical Companies
Iopromide - Supply Chain

Use Cases of Iopromide in Computed Tomography & Urography

Computed Tomography : In computed tomography, iopromide is predominantly used as a non-ionic, low-osmolar iodinated contrast agent, typically in concentrations such as iopromide 300 or 370 mg iodine/mL. It is administered intravenously to enhance soft tissue contrast and vascular structures during CT scans of the brain, chest, abdomen, and trauma cases. The key advantage of iopromide in CT imaging lies in its favorable safety profile, characterized by reduced osmolality and lower incidence of adverse reactions compared to older ionic agents. Its rapid distribution and consistent image enhancement support high-throughput CT workflows, making it well suited for hospitals and diagnostic imaging centers managing large patient volumes.
Angiography : For angiography applications, high-concentration iopromide formulations such as iopromide 370 are most commonly used due to their ability to provide strong vascular opacification. The agent is injected intra-arterially to visualize coronary, cerebral, and peripheral blood vessels with high clarity. Iopromide’s low viscosity and non-ionic nature allow smooth catheter injection and reduce patient discomfort during complex interventional procedures. These characteristics are particularly valuable in cardiovascular and neurovascular angiography, where image precision directly influences clinical outcomes. The predictable hemodynamic behavior of iopromide supports its use in advanced angiographic techniques, reinforcing its preference among interventional radiologists in tertiary care hospitals.
Urography : In urography, iopromide is widely used for intravenous urography and CT urography to assess renal anatomy and urinary tract function. Medium-concentration iopromide formulations are typically selected to balance optimal contrast enhancement with renal safety. Its high water solubility enables rapid renal excretion, allowing clear visualization of kidneys, ureters, and bladder during sequential imaging phases. A major advantage in urography is its relatively low nephrotoxic potential compared to older contrast agents, supporting safer use in patients requiring detailed urinary system evaluation. This makes iopromide a reliable choice in both routine diagnostic and preoperative urological imaging.

Recent Developments

Recent developments in Ultravist reflect sustained emphasis on enhancing diagnostic imaging contrast media performance and safety. Manufacturers are refining low-osmolar, non-ionic formulations to support high-resolution computed tomography and angiography while minimizing adverse reactions. A key trend is integration with advanced imaging protocols that favor reduced iodine doses and better patient tolerability. Growing adoption in oncology and cardiovascular diagnostics underscores demand for reliable vascular and soft-tissue enhancement. Strategic focus on regulatory compliance and clinical validation further bolsters market competitiveness and long-term use.

December 2025 : Bayer announced FDA 510(k) clearance for its MEDRAD Centargo multi‑patient CT injector to support a wider range of compatible contrast agent presentations, including single‑dose vials of Ultravist (iopromide), enhancing flexibility for high‑throughput imaging suites and facilitating waste reduction and operational efficiency in radiology practices.
June 2023 : The U.S. Food and Drug Administration approved Ultravist (iopromide‑300 and ‑370) for use in contrast‑enhanced mammography (CEM), making it the only iodine‑based contrast agent indicated to visualize known or suspected breast lesions in adults as an adjunct to mammography or ultrasound.

Impact of Industry Transitions on the Iopromide Market

As a core segment of the Pharmaceutical industry, the Iopromide market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Conventional Imaging Support to Integrated Diagnostic Workflow Solutions and Shift from Mature Markets to Rapid Adoption in Emerging Healthcare Economies have redefined priorities across the Pharmaceutical sector, influencing how the Iopromide market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Conventional Imaging Support to Integrated Diagnostic Workflow Solutions

The role of iopromide is shifting from a standalone contrast agent to becoming part of integrated diagnostic workflows within modern healthcare systems. Hospitals and imaging centers are increasingly aligning contrast media use with advanced imaging platforms and digital diagnostics. This transition is improving efficiency in radiology departments while enabling faster clinical decision-making. For example, coordinated use of contrast agents with high-resolution CT systems is enhancing throughput and patient management. This shift is influencing both pharmaceutical suppliers and healthcare providers to adopt more collaborative, system-oriented approaches.
02

Shift from Mature Markets to Rapid Adoption in Emerging Healthcare Economies

The iopromide market is transitioning toward greater demand in emerging economies as healthcare infrastructure expands. While traditionally dominated by North America and Europe, growth is now accelerating in Asia Pacific and Latin America due to increased investment in diagnostic imaging facilities. This shift is impacting global supply chains, with manufacturers focusing on regional distribution partnerships and localized strategies. For instance, rising patient volumes in urban hospitals are driving higher consumption of contrast agents. This transition is reshaping competitive dynamics and opening new revenue streams in previously underpenetrated markets.